| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tapan Behl, Ishnoor Kaur, Arun Kumar, Vineet Mehta, Gokhan Zengin, Sandeep Aror. Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy. Current gene therapy. vol 20. issue 3. 2021-08-18. PMID:32811394. |
multiple treatment options targeting dopaminergic neuronal regeneration, production of enzymes linked with dopamine synthesis, subthalamic nucleus neurons, regulation of astrocytes and microglial cells and potentiating neurotrophic factors, were established. |
2021-08-18 |
2023-08-13 |
Not clear |
| Ekaterina Dobryakova, Suzanne Zuckerman, Joshua Sandr. Neural correlates of extrinsic and intrinsic outcome processing during learning in individuals with TBI: a pilot investigation. Brain imaging and behavior. 2021-08-18. PMID:34406636. |
animal research shows that damage to dopaminergic pathways in the brain can lead to a disruption of dopamine tone and transmission. |
2021-08-18 |
2023-08-13 |
human |
| Kaavya Jayaramayya, Mahalaxmi Iyer, Dhivya Venkatesan, Venkatesh Balasubramanian, Arul Narayanasamy, Mohana Devi Subramaniam, Ssang Goo Cho, Balachandar Vellingir. Unraveling correlative roles of dopamine transporter (DAT) and Parkin in Parkinson's disease (PD) - A road to discovery? Brain research bulletin. vol 157. 2021-08-17. PMID:32035946. |
parkinson's disease (pd) is a neurodegenerative disorder accompanied by depletion of dopamine(da) and loss of dopaminergic (daergic) neurons in the brain that is believed to be responsible for the motor and non-motor symptoms of pd. |
2021-08-17 |
2023-08-13 |
Not clear |
| Polina Kosillo, Helen S Bateu. Dopaminergic Dysregulation in Syndromic Autism Spectrum Disorders: Insights From Genetic Mouse Models. Frontiers in neural circuits. vol 15. 2021-08-17. PMID:34366796. |
the dopamine hypothesis of asd postulates that dysregulation of dopaminergic projection pathways could contribute to the behavioral manifestations of asd, including altered reward value of social stimuli, changes in sensorimotor processing, and motor stereotypies. |
2021-08-17 |
2023-08-13 |
mouse |
| Polina Kosillo, Helen S Bateu. Dopaminergic Dysregulation in Syndromic Autism Spectrum Disorders: Insights From Genetic Mouse Models. Frontiers in neural circuits. vol 15. 2021-08-17. PMID:34366796. |
overall, we find considerable support for the idea that the dopamine system may be dysregulated in syndromic asds; however, there does not appear to be a consistent signature and some models show increased dopaminergic function, while others have deficient dopamine signaling. |
2021-08-17 |
2023-08-13 |
mouse |
| Darlene Mae Ortiz, Raly James Perez Custodio, Arvie Abiero, Chrislean Jun Botanas, Leandro Val Sayson, Mikyung Kim, Hyun Jun Lee, Hee Jin Kim, Youngdo Jeong, Sulmin Yoon, Yong Sup Lee, Jae Hoon Cheon. The dopaminergic alterations induced by 4-F-PCP and 4-Keto-PCP may enhance their drug-induced rewarding and reinforcing effects: Implications for abuse. Addiction biology. vol 26. issue 4. 2021-08-16. PMID:33135332. |
dopamine (da) receptor antagonists (sch23390 and haloperidol) were administered during cpp to evaluate the involvement of the mesolimbic dopaminergic system. |
2021-08-16 |
2023-08-13 |
Not clear |
| Conner W Wallace, Steve C Fordah. Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. Nutrition research reviews. 2021-08-16. PMID:34184629. |
obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. |
2021-08-16 |
2023-08-13 |
Not clear |
| Falaq Naz, Rahul, Mahino Fatima, Swaleha Naseem, Wasi Khan, Amal Chandra Mondal, Yasir Hasan Siddiqu. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology. vol 177. 2021-08-12. PMID:32707222. |
α-synuclein accumulation in the brain of flies (pd flies) leads to the damage of dopaminergic neurons, dopamine depletion, impaired muscular coordination, memory decline and increase in oxidative stress. |
2021-08-12 |
2023-08-13 |
drosophila_melanogaster |
| Jie Li, Chen Lu, Zilong Gao, Yifan Feng, Huoqing Luo, Tangsheng Lu, Xia Sun, Ji Hu, Yanli Lu. SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain. Neuropharmacology. vol 177. 2021-08-12. PMID:32710978. |
to verify the enhanced dopamine levels induce the faster antidepressant effects of snris, we employed dopamine receptor antagonists to specifically block the dopaminergic function. |
2021-08-12 |
2023-08-13 |
Not clear |
| Lisa M Smits, Stefano Magni, Kaoru Kinugawa, Kamil Grzyb, Joachim Luginbühl, Sonia Sabate-Soler, Silvia Bolognin, Jay W Shin, Eiichiro Mori, Alexander Skupin, Jens C Schwambor. Single-cell transcriptomics reveals multiple neuronal cell types in human midbrain-specific organoids. Cell and tissue research. vol 382. issue 3. 2021-08-10. PMID:32737576. |
human midbrain organoids (hmos) have been described to contain midbrain-specific dopaminergic neurons that release the neurotransmitter dopamine. |
2021-08-10 |
2023-08-13 |
human |
| Ana Martínez, Ponciano García-Gutiérrez, Rafael A Zubillaga, Jorge Garza, Rubicelia Varga. Main interactions of dopamine and risperidone with the dopamine D2 receptor. Physical chemistry chemical physics : PCCP. vol 23. issue 26. 2021-08-10. PMID:34159983. |
psychosis is one of the psychiatric disorders that is controlled by dopaminergic drugs such as antipsychotics that have affinity for the dopamine d2 receptor (drd2). |
2021-08-10 |
2023-08-13 |
Not clear |
| Hussein Ibrahim, Zoe Woodward, Jennifer Pooley, Edward William Richfiel. Rotigotine patch prescription in inpatients with Parkinson's disease: evaluating prescription accuracy, delirium and end-of-life use. Age and ageing. vol 50. issue 4. 2021-08-06. PMID:33264385. |
rotigotine patch, a trans-dermal dopamine agonist, is used acutely to replace oral dopaminergic medications for inpatients with parkinson's disease where enteral routes are no longer available, and is also an option in end-of-life care where patients can no longer swallow. |
2021-08-06 |
2023-08-13 |
Not clear |
| Jolanta Dorszewska, Marta Kowalska, Michał Prendecki, Thomas Piekut, Joanna Kozłowska, Wojciech Kozubsk. Oxidative stress factors in Parkinson's disease. Neural regeneration research. vol 16. issue 7. 2021-08-04. PMID:33318422. |
the first step in managing progressive pd is to optimize dopaminergic therapy by increasing the doses of dopamine agonists and l-dopa. |
2021-08-04 |
2023-08-13 |
Not clear |
| Tapan Behl, Ishnoor Kaur, Aayush Sehgal, Sukhbir Singh, Saurabh Bhatia, Ahmed Al-Harrasi, Gokhan Zengin, Adrian Gheorghe Bumbu, Felicia Liana Andronie-Cioara, Aurelia Cristina Nechifor, Daniela Gitea, Alexa Florina Bungau, Mirela Marioara Toma, Simona Gabriela Bunga. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications. International journal of molecular sciences. vol 22. issue 13. 2021-08-04. PMID:34201647. |
progressive degeneration of neurons and aggravation of dopaminergic neurons in the substantia nigra pars compacta results in the loss of dopamine in the brain of parkinson's disease (pd) patients. |
2021-08-04 |
2023-08-13 |
Not clear |
| Jianhua Su, Junhua Zhang, Rui Bao, Changbo Xia, Yu Zhang, Zhujun Zhu, Qi Lv, Yingjie Qi, Jianqin Xu. Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3β/PP2A pathway in Parkinson's disease. European journal of pharmacology. vol 907. 2021-08-03. PMID:34048739. |
parkinson's disease (pd) is a common neurological disorder worldwide, characterized by loss of dopaminergic neurons and decrease of dopamine content. |
2021-08-03 |
2023-08-13 |
mouse |
| Kouhei Oonuma, Takehiro G Kusakab. The complete cell lineage and MAPK- and Otx-dependent specification of the dopaminergic cells in the Ciona brain. Development (Cambridge, England). vol 148. issue 12. 2021-08-02. PMID:34121117. |
a recent study suggested that the transcription factors fer2 and meis directly regulate the dopamine synthesis genes in ciona, but the dopaminergic cell lineage and the gene regulatory networks that control the development of dopaminergic cells have not been fully elucidated. |
2021-08-02 |
2023-08-13 |
Not clear |
| Katarzyna Z Kuter, Łukasz Olech, Urszula Głowacka, Martyna Paleczn. Increased Beta-Hydroxybutyrate Level Is Not Sufficient for the Neuroprotective Effect of Long-Term Ketogenic Diet in an Animal Model of Early Parkinson's Disease. Exploration of Brain and Liver Energy Metabolism Markers. International journal of molecular sciences. vol 22. issue 14. 2021-07-30. PMID:34299176. |
locomotor activity, neuron count, dopaminergic terminal density, dopamine level, and turnover were analyzed at three time-points post-lesion, up to 4 weeks after the operation. |
2021-07-30 |
2023-08-13 |
human |
| Hexin Yan, Hui Zhao, Yunxiao Kang, Xiaoming Ji, Tianyun Zhang, Yu Wang, Rui Cui, Guoliang Zhang, Geming Sh. Parecoxib alleviates the motor behavioral decline of aged rats by ameliorating mitochondrial dysfunction in the substantia nigra via COX-2/PGE2 pathway inhibition. Neuropharmacology. vol 194. 2021-07-28. PMID:34089729. |
we found that parecoxib administration to aged rats for 10 weeks decreased cox-2/pge2 expression, increased tyrosine hydroxylase and dopamine transporter expression in nigrostriatal dopaminergic neurons, and alleviated motor behavioral decline. |
2021-07-28 |
2023-08-13 |
rat |
| Francesca V Lopez, Brittany Y Rohl, Aparna Wagle-Shukla, Dawn Bower. Sniffing Out Cognitive Decline in Patients with and without Evidence of Dopaminergic Deficit. Clinical parkinsonism & related disorders. vol 1. 2021-07-27. PMID:33969286. |
depletion of dopamine is a major neuropathological feature of parkinson's disease; however, 15% of patients with parkinsonian motor symptoms have neuroimaging evidence of intact dopaminergic function. |
2021-07-27 |
2023-08-13 |
Not clear |
| Ishnoor Kaur, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Lotfi Aleya, Simona Bunga. Connecting the dots between mitochondrial dysfunction and Parkinson's disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity. Environmental science and pollution research international. vol 28. issue 28. 2021-07-27. PMID:34053042. |
multiple neurological disorders occur as a consequence of impaired mitochondrial functioning, with greater sensitivity of dopaminergic (da) neurons to mitochondrial dysfunction, due to oxidative nature and low mitochondrial mass, thus supporting the contribution of mitochondrial impairment in parkinson's disorder (neuronal damage due to curbed dopamine levels). |
2021-07-27 |
2023-08-13 |
Not clear |